Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.38 |
| ▸ | PDE4A | P27815 | 7/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776479 | 0.83 | PDE4B (0.35) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL17844396 | 0.74 | GPR6 (0.40) | EGFR | |
| SCHEMBL5778854 | 0.74 | CSF1R (0.33) | — | |
| SCHEMBL16935388 | 0.74 | PDE9A (0.38) | TBK1 | |
| SCHEMBL18305797 | 0.73 | TRPV4 (0.34) | — | |
| SCHEMBL186585 | 0.71 | TRPV4 (0.52) | — | |
| SCHEMBL7360862 | 0.70 | PDE4D (0.54) | PDE4DPDE4BPDE4APDE4CCHEK1 | |
| SCHEMBL17837908 | 0.70 | GPR119 (0.53) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL28550646 | 0.69 | PDE4D (0.37) | EGFRMAPK8MAPK9PDE4DPDE4B | |
| SCHEMBL25987088 | 0.69 | PDE4D (0.37) | EGFRMAPK8MAPK9PDE4DPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1483257-A1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
| WO-2003076427-A1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | EGFR 4187/4885MAPK8 2862/4885MAPK9 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.